Tango Therapeutics, Inc.

Tango Therapeutics, Inc.verified

TNGX

Price:

$3.04

Market Cap:

$326.55M

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in...[Read more]

Industry

Biotechnology

IPO Date

2020-09-03

Stock Exchange

NASDAQ

Ticker

TNGX

The PE Ratio as of December 2024 (TTM) for Tango Therapeutics, Inc. (TNGX) is -2.64

According to Tango Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -2.64. This represents a change of -64.77% compared to the average of -7.49 of the last 4 quarters.

Tango Therapeutics, Inc. (TNGX) Historical PE Ratio (quarterly & annually)

How has TNGX PE Ratio performed in the past?

The mean historical PE Ratio of Tango Therapeutics, Inc. over the last ten years is -8.06. The current -2.64 PE Ratio has changed 3.17% with respect to the historical average. Over the past ten years (40 quarters), TNGX's PE Ratio was at its highest in in the September 2022 quarter at -2.82. The PE Ratio was at its lowest in in the June 2021 quarter at -55.39.

Quarterly (TTM)
Annual

Average

-8.06

Median

-7.04

Minimum

-11.67

Maximum

-5.89

Tango Therapeutics, Inc. (TNGX) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Tango Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 65.65%

Maximum Annual PE Ratio = -5.89

Minimum Annual Increase = -49.55%

Minimum Annual PE Ratio = -11.67

Quarterly (TTM)
Annual
YearPE RatioChange
2023-9.2056.35%
2022-5.89-49.55%
2021-11.6765.65%
2020-7.048.00%

Tango Therapeutics, Inc. (TNGX) Average PE Ratio

How has TNGX PE Ratio performed in the past?

The current PE Ratio of Tango Therapeutics, Inc. (TNGX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-8.92

5-year avg

-8.06

10-year avg

-8.06

Tango Therapeutics, Inc. (TNGX) PE Ratio vs. Peers

How is TNGX’s PE Ratio compared to its peers?

Tango Therapeutics, Inc.’s PE Ratio is greater than Third Harmonic Bio, Inc. (-10.88), greater than Cullinan Oncology, Inc. (-4.99), greater than Edgewise Therapeutics, Inc. (-22.36), less than Rallybio Corporation (-0.57), greater than Monte Rosa Therapeutics, Inc. (-4.84), less than Connect Biopharma Holdings Limited (7.21), greater than Tyra Biosciences, Inc. (-9.91), less than RAPT Therapeutics, Inc. (-0.63), less than Xilio Therapeutics, Inc. (-1.16), greater than Mineralys Therapeutics, Inc. (-4.16), greater than Foghorn Therapeutics Inc. (-3.45), less than Shattuck Labs, Inc. (-0.76), greater than Kymera Therapeutics, Inc. (-18.55), greater than Nurix Therapeutics, Inc. (-8.05), less than TCR2 Therapeutics Inc. (-0.38), greater than Revolution Medicines, Inc. (-13.06), less than Black Diamond Therapeutics, Inc. (-1.69), less than Atreca, Inc. (-0.06), less than Passage Bio, Inc. (-0.58), less than Relay Therapeutics, Inc. (-1.72), greater than Stoke Therapeutics, Inc. (-6.05), greater than Pliant Therapeutics, Inc. (-4.06), greater than Arvinas, Inc. (-4.38),

Build a custom stock screener for Tango Therapeutics, Inc. (TNGX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Tango Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Tango Therapeutics, Inc. (TNGX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Tango Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Tango Therapeutics, Inc.'s PE Ratio?

How is the PE Ratio calculated for Tango Therapeutics, Inc. (TNGX)?

What is the highest PE Ratio for Tango Therapeutics, Inc. (TNGX)?

What is the 3-year average PE Ratio for Tango Therapeutics, Inc. (TNGX)?

What is the 5-year average PE Ratio for Tango Therapeutics, Inc. (TNGX)?

How does the current PE Ratio for Tango Therapeutics, Inc. (TNGX) compare to its historical average?